Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Pinter

Showing results (81-90 of 135) with videos related to

Pageof 14
Sort By:
Paediatric Drugs|April 2, 2026
Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic DermatitisAmy S Paller, Andreas Pinter, Lara Wine Lee, et al.
The British Journal of Dermatology|December 22, 2023
Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS)Diamant Thaçi, Andreas Pinter, Michael Sebastian, et al.
The New England Journal of Medicine|February 7, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque PsoriasisRobert Bissonnette, Andreas Pinter, Laura K Ferris, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 6, 2023
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn studyLars Iversen, Curdin Conrad, Liv Eidsmo, et al.
JAMA Dermatology|April 13, 2022
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical TrialAmy S Paller, Marieke M B Seyger, Gabriel A Magariños, et al.
The British Journal of Dermatology|January 25, 2025
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension periodRichard B Warren, Mark Lebwohl, Diamant Thaçi, et al.
Dermatology and Therapy|November 22, 2024
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled TrialsJoseph F Merola, Alice B Gottlieb, Andreas Pinter, et al.
Rheumatology and Therapy|July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.
The Journal of Allergy and Clinical Immunology|August 27, 2019
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritusJonathan I Silverberg, Andreas Pinter, Grazyna Pulka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.
Pageof 14

Showing results (81-90 of 135) with videos related to

Sort By:
Pageof 14
Paediatric Drugs|April 2, 2026
Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic DermatitisAmy S Paller, Andreas Pinter, Lara Wine Lee, et al.
The British Journal of Dermatology|December 22, 2023
Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS)Diamant Thaçi, Andreas Pinter, Michael Sebastian, et al.
The New England Journal of Medicine|February 7, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque PsoriasisRobert Bissonnette, Andreas Pinter, Laura K Ferris, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 6, 2023
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn studyLars Iversen, Curdin Conrad, Liv Eidsmo, et al.
JAMA Dermatology|April 13, 2022
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical TrialAmy S Paller, Marieke M B Seyger, Gabriel A Magariños, et al.
The British Journal of Dermatology|January 25, 2025
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension periodRichard B Warren, Mark Lebwohl, Diamant Thaçi, et al.
Dermatology and Therapy|November 22, 2024
Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled TrialsJoseph F Merola, Alice B Gottlieb, Andreas Pinter, et al.
Rheumatology and Therapy|July 3, 2023
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic ArthritisBruce W Kirkham, Alexander Egeberg, Frank Behrens, et al.
The Journal of Allergy and Clinical Immunology|August 27, 2019
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritusJonathan I Silverberg, Andreas Pinter, Grazyna Pulka, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.
Pageof 14